---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-085061"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2026-07-20T20:06:12+00:00"
generated_at: "2026-07-20T20:07:06.163435+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elutia signs agreement to sell SimpliDerm business for up to $11M, focuses on NXT-41x launch

## Summary
- Total consideration up to $11M: $8M cash at closing plus up to $3M in technology transfer and commercial milestone payments over 18 months.
- Closing expected in H2 2026, subject to customary conditions; buyer is Cellution Biologics Inc.
- Proceeds provide non-dilutive capital to advance NXT-41x toward clearance and commercial launch in 2027.
- Divestiture sharpens Elutia's focus on the $1.5B plastic and reconstructive surgery market with NXT-41x.
- SimpliDerm is a human acellular dermis product for breast reconstruction; sale completes strategic review.

## SEC filing metadata
- accession: 0001104659-26-085061
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2026-07-20T20:06:12+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465926085061/0001104659-26-085061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465926085061/tm2620864d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-085061
- JSON: https://secwatch.observer/filing/0001104659-26-085061.json
- Plain text: https://secwatch.observer/filing/0001104659-26-085061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.